Meta Description: A new clinical trial investigates optical imaging for PD-1/PD-L1 in esophageal cancer using advanced spectroscopy systems and fluorescently labeled drugs.
A groundbreaking clinical trial has been announced, aiming to explore the use of advanced optical imaging to target PD-1/PD-L1 biomarkers in locally advanced esophageal cancer. Sponsored by University Medical Center Groningen and Martini Hospital Groningen, the study will evaluate the fluorescent agents Durvalumab-680LT and Nivolumab-800CW in combination with a spectroscopy imaging system. Currently listed as “not yet recruiting,” this trial offers insights into the development of precision cancer therapies.
In this article:
- What changed?
- What are the trial objectives?
- Who are the participants?
- FAQ
- Conclusion
- Disclaimer
- Announcement Link
What changed?
This newly announced trial represents a significant step in applying optical imaging techniques to identify and quantify PD-1 and PD-L1 expression in esophageal cancer. Rather than relying solely on traditional biopsy and immunohistochemistry, the study introduces the innovative use of fluorescent-labeled drugs in tandem with spectroscopy systems. As of September 2025, the trial has not yet begun recruiting participants.
The inclusion of digital imaging in oncological diagnostics aligns with recent trends in precision medicine. Researchers aim to provide more actionable information for clinicians while addressing the limitations of current tumor profiling methods.
What are the trial objectives?
The trial seeks to achieve multiple objectives:
- Assess the safety and efficacy of Durvalumab-680LT and Nivolumab-800CW as imaging agents.
- Determine how effectively the spectroscopy system can detect PD-1/PD-L1 biomarkers.
- Advance understanding of the tumor microenvironment in locally advanced esophageal cancer.
The dual-language optical agents Durvalumab-680LT and Nivolumab-800CW were specifically developed to bind to PD-1/PD-L1 with fluorescent tags, enhancing the visibility of these biomarkers. The spectroscopy system will be critical in capturing and analyzing this data, allowing for tumor identification with greater accuracy.
Who are the participants?
This trial will focus on patients diagnosed with locally advanced esophageal cancer. Specific inclusion and exclusion criteria have not yet been fully published, but similar studies often prioritize patients for whom standard-of-care treatments may be insufficient or those who show high PD-1/PD-L1 expression.
Because recruitment has not yet begun, clinicians and stakeholders should monitor this study’s listing closely for updates.
FAQ
1. What is the main goal of the trial?
The trial aims to evaluate how well optical imaging can identify biomarkers PD-1 and PD-L1 in esophageal cancer using labeled drugs and a spectroscopy system.
2. What are Durvalumab-680LT and Nivolumab-800CW?
These are experimental forms of immune-checkpoint inhibitors labeled with fluorescent tags to enhance detection during imaging.
3. When will recruitment begin?
As of now, the trial is “not yet recruiting.” Check the ClinicalTrials.gov link for updates.
4. Will this imaging technique replace biopsy methods?
The study aims to complement, not replace, traditional biopsy techniques by providing real-time insights.
Conclusion
This clinical trial could redefine how oncologists approach biomarker detection in esophageal cancer, incorporating a novel imaging platform to improve precision. Professionals interested in imaging modalities, immune-oncology, or esophageal cancer treatments should follow this study closely for outcomes.
Disclaimer
This article is for informational purposes only and is not intended as legal or clinical advice. Always consult regulatory guidance or a qualified expert.
Announcement Link
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07196384?term=medical+device